TC
VBIV

TFS Capital’s VBI Vaccines, Inc. New Common Stock (Canada) VBIV Stock Holding History

TFS Capital’s Portfolio VBIV Stock Details VBIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-759
Closed -$99K – 390
2017
Q2 		$99K Buy
759
+374
+97% +$50.5K 0.04% 551
2017
Q1 		$63K Buy
+385
New +$52.1K 0.02% 615

Other funds holding VBIV

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
CV
Clarus Ventures Cambridge, Massachusetts $425M AUM 26.13% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
FPC
Falcon Point Capital San Francisco, California $11.9M AUM 55.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TFS Capital's VBIV Position: Q3 2017 in Review

TFS Capital sold out of VBI Vaccines, Inc. New Common Stock (Canada) (VBIV) in Q3 2017, closing a stake of 759 shares — an estimated $99K sold.

TFS Capital first reported a position in VBIV in Q1 2017 and held it in 2 quarters. The position peaked at $99K in Q2 2017. 44 funds tracked by Wall St. Rank hold VBIV as of Q3 2017.

  • TFS Capital reported no remaining VBI Vaccines, Inc. New Common Stock (Canada) position as of Q3 2017 after selling out during the quarter.
  • TFS Capital sold 759 VBI Vaccines, Inc. New Common Stock (Canada) shares in Q3 2017, an estimated $99K.
  • TFS Capital first reported a position in VBI Vaccines, Inc. New Common Stock (Canada) in Q1 2017 and held it in 2 quarters.
  • TFS Capital's VBI Vaccines, Inc. New Common Stock (Canada) position peaked at $99K in Q2 2017.
  • 44 funds tracked by Wall St. Rank held VBI Vaccines, Inc. New Common Stock (Canada) as of Q3 2017.

Based on TFS Capital's 13F filing for Q3 2017.